Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering




Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) — Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.

The notes will be senior, unsecured obligations of Indivior and will accrue interest at a rate of 0.625% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2026. The notes will mature on March 15, 2031, unless earlier repurchased, redeemed or converted. Before December 16, 2030, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after December 16, 2030, noteholders will have the right to convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Indivior will settle conversions by paying or delivering cash and, if applicable, shares of its common stock.. The initial conversion rate is 24.0033 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $41.66 per share of common stock. The initial conversion price represents a premium of approximately 35.0% over the last reported sale price of the common stock on The Nasdaq Global Select Market on March 12, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Indivior’s option at any time, and from time to time, on or after March 20, 2029 and on or before the 25th scheduled trading day before the maturity date, but only if the last reported sale price per share of Indivior’s common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If certain events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require Indivior to repurchase their notes at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

Indivior estimates that the net proceeds to it from the offering will be approximately $437.7 million (or approximately $486.4 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and Indivior’s estimated offering expenses. Indivior intends (1) to use approximately $239 million of the net proceeds from the offering together with approximately $102 million of cash on hand to repay borrowings under and terminate the note purchase agreement that governs its term loan and revolving credit facility, (2) to use approximately $75.0 million of the net proceeds from the offering to repurchase approximately 2.4 million shares of its common stock from certain purchasers of the notes concurrently with the pricing of the offering in privately negotiated transactions effected through one of the initial purchasers or an affiliate thereof, at a price per share equal to the last reported sale price per share of the common stock on The Nasdaq Global Select Market on March 12, 2026 and (3) the remainder of the net proceeds from the offering for general corporate purposes.

The concurrent repurchases of approximately $75.0 million of common stock described above may have resulted in the common stock trading at prices that were higher than would be the case in the absence of these repurchases, which may have resulted in a higher initial conversion price for the notes.

The notes were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope.

Important Cautionary Note Regarding Forward-looking Statements

Certain statements contained herein are forward-looking statements. Forward-looking statements include, among other things, express and implied statements pertaining to: (i) whether Indivior will issue the notes; (ii) the timing of the closing of the offering; (iii) the expected amount and intended use of the net proceeds from the offering; (iv) Indivior’s expectations regarding the effects of the concurrent common stock repurchases; and (v) statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. For information about some additional risks and important factors that could affect our future results and financial condition, see the discussion of “Risk Factors” in our Annual Report on Form 10-K filed February 26, 2026 and our other filings with the SEC.

We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement.

For Further Information

Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com

Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results




Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.

“2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth” said James Helliwell, CEO of Eupraxia. “As we look ahead to an exciting year, we anticipate multiple clinical readouts from the ongoing RESOLVE trial and the initiation of additional clinical programs in new indications to further expand and strengthen our pipeline”

Recent Operational and Financial Highlights

  • On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.
  • On January 8, 2026, the Company announced positive tissue health data from its ongoing RESOLVE trial in EoE demonstrating near-complete improvement on biopsy. 
  • On February 20, 2026, the Company announced the closing of a public offering of Common Shares (the “Offering”). The Company issued 7,607,145 Common Shares at a price of $7.00 per Common Share for gross proceeds of approximately $63.2 million which included the issuance of 1,178,571 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters, and 1,428,571 Pre-Funded Warrants at a price of $6.99999 per Pre-Funded Warrant.

Fourth Quarter 2025 Financial Review

The Company incurred a net loss of $16.7 million for the three months ended December 31st, 2025, versus a net loss of $7.5 million for the three months ended December 31st, 2024. The increase in net loss was primarily due to an increase in research and development costs associated with the EP-104GI program and increased general and administrative costs.

The Company had cash of $80.5 million as of December 31st, 2025, up from $33.1 million at the end of the fourth quarter of 2024.

The Company anticipates that existing cash reserves and proceeds from the Offering and anticipated future exercise of in-the-money warrants, will be sufficient to fund the Company into the second half of 2028.

As of December 31st 2025, the Company had 51,939,206 common shares and 8,355,638 preferred shares outstanding.

Potential Impact of Tariffs

Management continues to monitor the North American trade situation that began with the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods. At present, U.S. tariffs are in flux following the recent U.S. Supreme Court decision regarding the scope of executive tariff authority that struck down certain tariffs that had been in place.

Eupraxia manufactures its clinical supplies of EP-104IAR and EP-104GI in the U.S. by a third-party. The Company expects to continue to access manufactured products from the U.S.

The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates.

Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia’s business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves.

Financial Statements and Management Discussion & Analysis

Please see the audited consolidated financial statements and related MD&A for more details. The audited consolidated financial statements for the year ended December 31, 2025, and related MD&A have been reviewed and approved by Eupraxia’s Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at sedarplus.ca and which is also available on the Company’s website at www.eupraxiapharma.com.

About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia’s Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia’s EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “suggests”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes”, “potential” or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company’s next phase of growth; the expected cash runway to fund pipeline development and operations into the second half of 2028; the use of proceeds from the Offering; the anticipated proceeds from future exercise of in-the-money warrants; the Company’s expectation that it will continue to access manufactured products from the U.S.; the potential imposition of a new reciprocal tariff rate; the Company’s product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company’s product candidates; the results gathered from studies and trials of Eupraxia’s product candidates and the timing of the release thereof; the potential for the Company’s technology to impact the drug delivery process; potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia’s management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company’s ability to obtain positive results from the Company’s research and development activities, including clinical trials; and the Company’s ability to protect patents and proprietary rights. Although Eupraxia’s management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company’s limited operating history; the Company’s novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company’s current license agreement may not provide an adequate remedy for its breach by the licensor; the Company’s technology may not be successful for its intended use; the Company’s future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company’s clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company’s ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company’s operations; the Company’s restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company’s common share price; and other risks and uncertainties described in more detail in Eupraxia’s public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results

VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results




VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results

TORONTO, March 12, 2026 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth quarter and year ended December 31, 2025.

The Company now expects to release its financial results on Wednesday, March 18, 2026, after market close. VitalHub will host a conference call to discuss the results on Thursday, March 19 at 8:00am EST. The change in timing reflects the need for additional time to finalize the Company’s annual financial statements.

To register for the conference call please visit: https://us06web.zoom.us/webinar/register/WN_k8_Av320RimXFXW0CFzQEA

About VitalHub

VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub’s comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,300 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 700 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit www.vitalhub.com and LinkedIn.

Contact Information

Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
christian.sgro@vitalhub.com

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
dan.matlow@vitalhub.com

Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

Surgery Partners, Inc. Names Lloyd Dean to Board of Directors




Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors.

Mr. Dean is the former Chief Executive Officer of CommonSpirit Health, one of the largest nonprofit health systems in the United States, with 142 hospitals, over 1,000 care sites, 25,000 physicians, and 150,000 employees across 21 states. From 2019 to 2022, he led the formation and integration of CommonSpirit, advancing clinical quality, operational performance, and community health initiatives at national scale. Prior to CommonSpirit, Mr. Dean served as President and CEO of Dignity Health, where he strengthened patient experience, expanded partnerships, and elevated the organization’s leadership in delivering compassionate, high‑quality care.

A nationally recognized healthcare leader, Mr. Dean has long championed efforts to reduce health disparities, strengthen the health care workforce, and advance equitable access to care. He has served as an adviser to multiple Presidential Administrations on issues including the Affordable Care Act and COVID‑19 vaccination efforts. Mr. Dean has also held several federal and state appointments focused on public health, economic development, and workforce planning.

Mr. Dean serves on the boards of McDonald’s Corporation—where he chairs the Board Human Resources & Compensation Committee—Guidehouse, Nox Health, and Progyny, and is a Senior Advisor to Bain Capital. He holds a B.S. in sociology and a master’s degree in educational leadership from Western Michigan University, along with multiple honorary doctorates.

“We are honored to welcome Lloyd to the Surgery Partners Board,” said Blair Hendrix, Chairman of Surgery Partners’ Board of Directors. “Lloyd is a nationally respected leader with deep experience advising health systems and shaping public policy. His insights will be invaluable as we continue to expand high‑quality, cost‑effective surgical care across the country.”

“I am excited to join the Board at a time of meaningful growth and opportunity for Surgery Partners,” said Mr. Dean. “The Company is well positioned to continue leading the shift toward high‑value outpatient surgical care, and I look forward to supporting its important mission.”

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

Contact

Surgery Partners Investor Relations

(615) 234-8940

IR@surgerypartners.com

GlycoPezil Supplement Claims Evaluated – Complete Investigation of the Blood Sugar Support Ingredients

GlycoPezil Supplement Claims Evaluated – Complete Investigation of the Blood Sugar Support Ingredients




GlycoPezil Supplement Claims Evaluated – Complete Investigation of the Blood Sugar Support Ingredients

A 2026 consumer research report examining GlycoPezil’s ingredient research references, proprietary blend structure, pricing transparency, and verification considerations for adults researching blood sugar support supplements

Lakeland, FL, March 12, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

In this report, the word “effectiveness” refers strictly to how GlycoPezil’s marketing language describes potential outcomes — not to any clinically proven result. No published clinical trial appears to have evaluated GlycoPezil as a proprietary formula.

If you’ve been researching blood sugar support supplements lately, GlycoPezil is likely one of the names you’ve come across. The product has been drawing real consumer attention — particularly among adults researching ways to support metabolic wellness and glucose balance over time.

Consumers searching terms such as “GlycoPezil review,” “does GlycoPezil work,” “GlycoPezil ingredients,” or “GlycoPezil blood sugar supplement” are typically trying to answer one specific question: how does the product’s marketing language connect to the actual ingredient research? That’s exactly what this report examines.

GlycoPezil Supplement Claims Evaluated Complete Investigation of the Blood Sugar Support Ingredients

This report examines the company’s published ingredient information, scientific references cited on the official website, and publicly available policy details so readers can independently evaluate the product’s claims.

Current product details, pricing, and terms are available here: View the current GlycoPezil offer (official GlycoPezil page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement, especially if you are managing blood sugar concerns or taking prescription medications.

What Is GlycoPezil

GlycoPezil is a dietary supplement marketed as a blood sugar support formula delivered in liquid drop form. The company’s product page describes it as a proprietary blend of eight carefully selected ingredients designed to support healthy blood sugar levels and overall metabolic well-being, positioning the formula for adults who want to maintain balanced glucose levels as part of a daily wellness routine.

According to the official website, GlycoPezil is manufactured in the United States from a combination of domestic and foreign-sourced ingredients. The product page states that the formula is produced in an FDA-registered facility following GMP (Good Manufacturing Practices) guidelines. It’s worth understanding what that means: FDA registration of a manufacturing facility confirms it is subject to federal inspection and operates under manufacturing standards. It is not an FDA review, approval, or endorsement of the product itself or any claims made about it.

The company describes GlycoPezil as a natural formula with plant-based ingredients, marketed as non-habit forming and easy to incorporate into a daily routine in drop form. The product is sold exclusively through the official website, with the company advising consumers that product authenticity and refund eligibility may not be guaranteed through unauthorized third-party sellers.

GlycoPezil Ingredient Claims: What the Company States and How to Evaluate It

The central marketing positioning of GlycoPezil connects its proprietary ingredient blend to support for healthy blood sugar levels, energy support, and metabolic balance. The company’s product page describes the formula as designed to help the body maintain balanced glucose levels and support metabolic well-being, citing clinical research as the basis for its ingredient selection.

The product’s promotional materials describe certain ingredient mechanisms in strong biological terms, including references to hormone signaling pathways and metabolic activity. These descriptions appear in the company’s marketing narrative and should not be interpreted as independently verified clinical outcomes without controlled studies on the finished formulation. They reflect how the brand positions its ingredients — not conclusions drawn from clinical trials evaluating GlycoPezil as a complete product.

There is genuine published research on individual compounds associated with blood sugar support categories. A substantial body of peer-reviewed literature covers nutrients such as Vitamin D, Vitamin C, B vitamins, and botanical extracts in the context of metabolic health and glucose regulation. GlycoPezil’s own scientific reference section cites published studies in this space, and those citations point to real peer-reviewed work.

The distinction between ingredient research and finished product testing is one of the most important factors when evaluating any dietary supplement. Studies cited in marketing materials typically examine isolated compounds under controlled conditions at specific dosages — not the proprietary blend contained in a specific supplement formula. That gap isn’t unique to GlycoPezil; it’s a category-wide reality. But it’s the single most important thing to understand when reading a supplement’s marketing claims alongside its referenced science.

As of this report, no published clinical trial appears to have evaluated GlycoPezil as a finished proprietary formula. Consumers searching for “GlycoPezil legit” or “GlycoPezil ingredients research” should carry that distinction clearly into their evaluation.

Additionally, some specific ingredient designations described in GlycoPezil’s marketing materials use terminology that does not appear in standard peer-reviewed scientific nomenclature. Consumers who want to cross-reference specific compound claims should verify ingredient names against recognized databases such as PubMed or the FDA’s dietary supplement ingredient directory before drawing conclusions about the underlying research basis.

What Published Blood Sugar Research Actually Covers

Understanding the broader ingredient research landscape puts GlycoPezil’s marketing claims in proper context — and gives a more useful answer than a simple yes-or-no on whether the product works.

Vitamin D has been studied extensively in relation to type 2 diabetes risk, beta cell function, and insulin sensitivity. Multiple peer-reviewed analyses have examined associations between Vitamin D status and metabolic outcomes, and GlycoPezil’s own reference section cites several of these studies directly.

Vitamin C has been evaluated in published research for its potential role in metabolic health and glucose management. Peer-reviewed narrative reviews have noted possible supportive effects for adults managing blood sugar concerns, with mechanisms often discussed in the context of oxidative stress reduction and fat metabolism support.

B vitamins, including B12, have been reviewed in published literature for their role in metabolic pathways and their relationship to diabetes-adjacent concerns, including nerve health and metabolic enzyme function.

In the botanical category, capsaicin — the active compound in cayenne — has peer-reviewed research examining effects on metabolism and glucose uptake. Green tea catechins, particularly EGCG, have accumulated evidence across multiple controlled studies on metabolic outcomes. Maca root (Lepidium meyenii) has been evaluated in randomized controlled trials for tolerability and safety, with acceptability research published in peer-reviewed journals.

These are real findings on real compounds. What they all have in common is that they tested isolated ingredients at known, disclosed dosages — often significantly higher than what a multi-ingredient proprietary blend can distribute across its full formula in a single serving. Treating those findings as proof of what a finished supplement will do would misrepresent what the research actually demonstrated.

That context isn’t meant to dismiss GlycoPezil’s ingredient selection. It’s meant to give you the accurate framework for understanding what the cited research does and doesn’t support.

GlycoPezil Proprietary Blend Structure: What It Means for You

GlycoPezil is formulated as a proprietary blend — a common structure across the supplement industry where the total blend volume is disclosed but individual ingredient amounts per serving are not. This protects the company’s formulation trade secrets, but it does limit your ability to compare each ingredient’s dosage against what clinical studies examined.

For context: published research on blood sugar-relevant nutrients and botanicals often examines single compounds at specific daily amounts. A multi-ingredient proprietary blend distributes its total volume across all listed ingredients simultaneously. Without disclosed individual amounts, there is no way to confirm or rule out research-level dosing from the label alone.

If knowing exact per-ingredient amounts matters to your purchasing decision, the most direct path is contacting the manufacturer directly. Some companies provide that information on request even when it isn’t listed publicly on the label.

Understanding proprietary blend structure won’t tell you whether a product is effective. What it does tell you is the exact boundary of what the label itself can confirm — which is a useful distinction to carry into any supplement purchase decision.

GlycoPezil Pricing and Purchase Structure

According to pricing information published on the official website at the time of this report, GlycoPezil is available in several multi-bottle packages. The company’s published pricing describes a 6-bottle option at $49 per bottle (listed total $294 with free US shipping), a 3-bottle option at $69 per bottle (listed total $207 with free US shipping), and a 2-bottle option at $89 per bottle (listed total $178 with a shipping charge).

According to the product page, all purchases are described as one-time payments with no automatic rebilling or subscription charges without explicit consent. The product page states that a majority of customers select the 6-bottle package as part of longer-term use plans described by the company.

Pricing and availability are subject to change. Readers can confirm current terms at the source: View the current GlycoPezil offer (official GlycoPezil page).

GlycoPezil Refund Policy: Reading the Full Terms Before You Buy

The company’s published materials reference a 60-day money-back guarantee. If you’re considering a purchase based on that guarantee, the complete return policy is worth reading carefully before you commit — specific conditions apply that differ from a straightforward full refund.

According to the return policy published on the official website at the time of this report, consumers requesting a refund should contact customer support by email at contact@customercs.com or by phone at +1 (507) 448-8190. The published policy states that return shipping costs are the customer’s responsibility and that the return process may take up to 30 days.

The policy also specifies that all bottles in the original order must be returned, that only sealed products are eligible for refund, and that a 30-day minimum usage period is required before a refund request will be accepted. A 15% restocking fee is deducted from the total refund amount, and shipping fees are described as non-refundable. Fulfilled orders cannot be canceled or refunded after shipping unless delivery denial upon arrival is confirmed, and chargebacks in progress eliminate refund eligibility through the company.

Retain all purchase confirmations and review the complete policy on the official website. The terms above are as published at the time of this report and are subject to change.

GlycoPezil Customer Testimonials: What the Company’s Own Disclosures Say

The official GlycoPezil website includes customer testimonials describing individual experiences with the product. The site’s own disclaimer states these examples may not represent typical results and should not be interpreted as guarantees of performance. The company explicitly notes that testimonials may not reflect the average buyer’s experience and are not intended to guarantee that any person will achieve the same or similar results.

Individual outcomes with dietary supplements vary based on baseline health, age, lifestyle factors, concurrent medications, and consistency of use. The results described in any testimonial reflect one person’s experience under their specific circumstances — not a predictable range across all users.

Who May Want to Research GlycoPezil Further

Based on the product’s published positioning and delivery format, GlycoPezil may be relevant to adults researching liquid-format blood sugar support supplements as one piece of a broader wellness approach that also includes balanced nutrition and regular physical activity.

Adults who rely heavily on transparent per-ingredient dosing for clinical comparison may find the proprietary blend structure limits that evaluation from the label alone — though asking the manufacturer directly is always an option. Anyone managing a diagnosed metabolic condition or taking prescription medications for blood sugar should speak with a healthcare provider before adding any supplement to their routine.

Dietary supplements are regulated differently from pharmaceutical drugs. The FDA does not evaluate supplement efficacy claims before products reach market. GlycoPezil’s own website confirms that its statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

View the current GlycoPezil offer (official GlycoPezil page)

Consumer Verification Checklist: What to Confirm Before Ordering

Read the complete refund policy before purchasing. The 60-day guarantee comes with a 30-day minimum usage requirement, a 15% restocking fee, return shipping at your cost, and a requirement that bottles be returned sealed. Knowing these terms upfront eliminates surprises if you decide to return the product.

Separate ingredient research from product research. GlycoPezil’s reference section links to published studies on individual nutritional compounds — not on GlycoPezil’s finished formula. That’s a meaningful distinction when setting expectations about what the science actually supports.

Cross-reference ingredient names with scientific databases. Some compound designations in the marketing materials don’t appear in standard peer-reviewed nomenclature. PubMed and the FDA’s dietary supplement ingredient directory are good places to start that verification.

Talk to your healthcare provider first. This is the most important step for anyone currently taking prescription medications for blood sugar management, living with diabetes or prediabetes, or managing related metabolic conditions. No dietary supplement should replace prescribed medical care, and a clinician who knows your health history is the right person to advise whether adding anything new makes sense for you.

Confirm current pricing and terms directly. Promotional pricing, multi-bottle offers, and refund terms can change without notice. Always verify on the official website before completing a purchase.

Consumer Questions About GlycoPezil

Is GlycoPezil FDA approved?

No — and that’s true of virtually all dietary supplements. Under current federal law, dietary supplements do not require FDA approval before they can be sold, and the FDA does not evaluate supplement efficacy claims prior to market entry. The website states that GlycoPezil is manufactured in an FDA-registered, GMP-certified facility. That refers to manufacturing standards and inspection eligibility — not FDA approval or endorsement of the product itself.

What ingredients does GlycoPezil contain?

The company describes GlycoPezil as an eight-ingredient proprietary blend formulated to support blood sugar balance. The scientific reference section on the product page cites published research covering Vitamin D, Vitamin C, B vitamins, and botanical compounds relevant to metabolic health. Consumers should verify the specific ingredient list on the official website and cross-reference any compound names with recognized scientific databases such as PubMed before drawing conclusions.

Can the research cited on the GlycoPezil website be verified?

Yes — the official website links to published peer-reviewed studies on individual nutritional compounds in the blood sugar and metabolic health space. Those studies can be looked up directly in PubMed or the relevant journal archives. The important thing to keep in mind is that those studies examined individual compounds at specific dosages under controlled conditions, not GlycoPezil’s proprietary formula as a finished product. That distinction matters when interpreting what the cited science does and doesn’t support.

Does GlycoPezil work for both men and women?

The company’s product page markets GlycoPezil broadly to adults seeking blood sugar support. Published research on individual compounds in this category has included both male and female study populations, though outcomes vary based on hormonal differences, baseline health, age, and other individual factors. A healthcare provider who knows your health history is better positioned than any supplement label to advise whether a product like this is appropriate for your situation.

What is the GlycoPezil refund policy?

The company’s published refund policy provides a 60-day window for requests, with several specific conditions: a 30-day minimum usage requirement, a 15% restocking fee, return shipping at the buyer’s cost, and a requirement that all bottles in the original order be returned in sealed condition. Review the complete return policy on the official website before purchasing and retain all order confirmations.

How long does GlycoPezil take to show results?

The company’s marketing language describes the formula as designed for consistent daily use over time, rather than for immediate results. Individual timelines depend on factors including baseline health, dietary habits, physical activity, age, and how consistently the product is used. The site’s own disclaimer notes that testimonial results may not reflect the typical buyer’s experience and should not be interpreted as guaranteed.

Where is GlycoPezil sold?

According to the company’s website, GlycoPezil is only available through its official website at glycopezilofficial.com. The company advises against purchasing through third-party marketplaces, noting that product authenticity and refund eligibility may not be guaranteed through unauthorized sellers.

What does “manufactured in an FDA-registered facility” mean?

An FDA-registered facility is a manufacturing site that has completed registration with the FDA as required by federal law and is subject to FDA inspection. GMP certification means the facility follows Good Manufacturing Practices for dietary supplements. Neither designation means the FDA has reviewed, tested, approved, or endorsed any specific product made at that location. They are manufacturing standards designations — not product safety or efficacy certifications.

Summary of Key Considerations

GlycoPezil is a dietary supplement marketed as a blood sugar support formula in liquid drop form, built around a proprietary blend of eight ingredients. The company cites published scientific research in its positioning, and the reference section includes citations to peer-reviewed work on individual nutritional compounds in the metabolic and glucose health space.

A few distinctions are worth carrying into any final decision. The cited research covers individual compounds studied in isolation — not GlycoPezil’s finished formula. No published clinical trial appears to have evaluated GlycoPezil as a complete formulation. Some ingredient designations in the marketing materials should be cross-referenced with scientific databases before being taken at face value. And the refund policy includes conditions — a 15% restocking fee, a 30-day minimum usage requirement, and buyer-paid return shipping — that differ meaningfully from a straightforward money-back guarantee.

The company states that GlycoPezil is manufactured under GMP standards in an FDA-registered facility, that all purchases are one-time payments with no automatic rebilling, and that the product is not intended to diagnose, treat, cure, or prevent any disease per the FDA disclaimer on the product’s own website.

Consumers who want to review full product details, current pricing, and published policy terms can do so directly. View the current GlycoPezil offer (official GlycoPezil page).

Contact Information

Product: GlycoPezil

Official Website: glycopezilofficial.com

Customer Support Email: contact@customercs.com

Customer Support Phone: +1 (507) 448-8190

Disclaimers

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are managing blood sugar concerns.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. GlycoPezil is a dietary supplement, not a medication. If you are currently taking prescription medications for blood sugar management, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting GlycoPezil or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. Testimonials on the official website represent individual submitted experiences and, per the company’s own disclaimer, may not reflect the typical buyer’s experience.

FTC Affiliate Disclosure: This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from the official website and published research.

Pricing Disclaimer: All prices, discounts, promotional offers, and refund terms mentioned were accurate at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing and full terms on the official GlycoPezil website before making any purchase decision.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information

CONTACT: Email: contact@customercs.com
Phone: +1 (507) 448-8190

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio Announces Q4 and year-end 2025 Shareholder Update Call




Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Conference Call to be held on April 2nd, 2026 at 5:00 PM EST

NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.

The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call.

Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call.

A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio’s website, https://www.precipiodx.com/investors/.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Inquiries:

investors@precipiodx.com

+1-203-787-7888 Ext. 523

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026




Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.

The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2025 results and an update on business activities. Details for the call are as follows:

Dial in information:

Domestic: +1-800-579-2543
International: +1-785-424-1789
Conference ID: CLLSFY
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.  

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026




EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026

Disclosure of Share Capital and Voting Rights Outstanding
as of March 11, 2026

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Paris, France (March 12, 2026 – 6:00 pm) – As of March 11, 2026, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.

  March 11, 2026
Shares outstanding 463,289,594
Number of real voting rights (excluding treasury shares) 460,461,195
Theoretical number of voting rights (including treasury shares) 463,289,594

It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article 23 of EssilorLuxottica’s by-laws1.

1EssilorLuxottica’s by-laws are available on the Company’s website under the section Governance / Publications.

Attachment

PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters

PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters




PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters

ST. LOUIS and HINTON, West Virginia, March 12, 2026 (GLOBE NEWSWIRE) — PracticeLink, the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, is pleased to announce the launch of its 2026 webinar series designed specifically for healthcare recruiters and talent acquisition professionals.

This free, monthly webinar series will provide practical insights and strategies to help healthcare organizations attract, recruit and retain top medical talent in an increasingly competitive hiring environment. Each session will feature expert perspectives from PracticeLink leaders as well as strategic partners with specialized expertise in physician recruitment and workforce strategy.

The series will kick off on March 18 with the first webinar, “Is Your Job Post Working? Writing & Optimizing Listings for Visibility,” and will feature insights from strategic partner Inkwise Consulting. The session, which begins at 12:00 p.m. Central Time, will offer tips for optimizing job descriptions for searchability, clarity and candidate relevance to help healthcare employers ensure their listings reach and resonate with the right candidates.

Attendees can register for the “Is Your Job Post Working? Writing & Optimizing Listings for Visibility” webinar by clicking this link.

Additional topics throughout the 2026 series will include wellness in recruitment, job advertisement optimization, compensation modeling and the impact of immigration policy on healthcare recruitment. Webinars will be held monthly throughout 2026 and are open to healthcare employers seeking new insights and tools to improve their recruitment strategies.

For more information, visit PracticeLink.com.

PracticeLink continues to offer its renowned PracticeLink Job Board, which is free for physicians to search and respond to job opportunities from 8,000 hospitals, medical groups and private practices listing more than 40,000 physician job opportunities. Recruiters benefit from the PracticeLink Recruitment Management System and PRO Marketing Suite. PracticeLink also offers PracticeLink Magazine, the free, award-winning career advancement publication for physicians that reaches 95,000 residents through quarterly themed issues. Click here to request your free subscription.

About PracticeLink
Established in 1994, PracticeLink connects physicians and advanced practitioners in all specialties with opportunities at more than 8,000 health systems, hospitals, medical groups, and private practices. PracticeLink improves the physician recruitment process through people, technology, and education—helping get physicians to the communities where they are needed most.

Follow PracticeLink on Facebook, LinkedIn, Instagram, X (formerly Twitter) and TikTok.

Contact
Christy Bray
Chief Customer Officer
Christy.Bray@PracticeLink.com

PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters

PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters




PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters

ST. LOUIS and HINTON, West Virginia, March 12, 2026 (GLOBE NEWSWIRE) — PracticeLink, the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, is pleased to announce the launch of its 2026 webinar series designed specifically for healthcare recruiters and talent acquisition professionals.

This free, monthly webinar series will provide practical insights and strategies to help healthcare organizations attract, recruit and retain top medical talent in an increasingly competitive hiring environment. Each session will feature expert perspectives from PracticeLink leaders as well as strategic partners with specialized expertise in physician recruitment and workforce strategy.

The series will kick off on March 18 with the first webinar, “Is Your Job Post Working? Writing & Optimizing Listings for Visibility,” and will feature insights from strategic partner Inkwise Consulting. The session, which begins at 12:00 p.m. Central Time, will offer tips for optimizing job descriptions for searchability, clarity and candidate relevance to help healthcare employers ensure their listings reach and resonate with the right candidates.

Attendees can register for the “Is Your Job Post Working? Writing & Optimizing Listings for Visibility” webinar by clicking this link.

Additional topics throughout the 2026 series will include wellness in recruitment, job advertisement optimization, compensation modeling and the impact of immigration policy on healthcare recruitment. Webinars will be held monthly throughout 2026 and are open to healthcare employers seeking new insights and tools to improve their recruitment strategies.

For more information, visit PracticeLink.com.

PracticeLink continues to offer its renowned PracticeLink Job Board, which is free for physicians to search and respond to job opportunities from 8,000 hospitals, medical groups and private practices listing more than 40,000 physician job opportunities. Recruiters benefit from the PracticeLink Recruitment Management System and PRO Marketing Suite. PracticeLink also offers PracticeLink Magazine, the free, award-winning career advancement publication for physicians that reaches 95,000 residents through quarterly themed issues. Click here to request your free subscription.

About PracticeLink
Established in 1994, PracticeLink connects physicians and advanced practitioners in all specialties with opportunities at more than 8,000 health systems, hospitals, medical groups, and private practices. PracticeLink improves the physician recruitment process through people, technology, and education—helping get physicians to the communities where they are needed most.

Follow PracticeLink on Facebook, LinkedIn, Instagram, X (formerly Twitter) and TikTok.

Contact
Christy Bray
Chief Customer Officer
Christy.Bray@PracticeLink.com